A double-blind, randomized, placebo-controlled study assessing effct of Age, Gender and Obesity on the Single Dose Pharmacokinetics (PK) of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in healthy subjects.

Trial Profile

A double-blind, randomized, placebo-controlled study assessing effct of Age, Gender and Obesity on the Single Dose Pharmacokinetics (PK) of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in healthy subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Omarigliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Most Recent Events

    • 23 Jul 2013 New trial record
    • 23 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top